29 research outputs found
Second line chemotherapy in non-small-cell lung carcinoma: A single-institution experience
Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab
The adverse effects of regimes in cancer treatment have forced us to
change to new targeted therapy options. Understanding these side
effects, which can lead to discontinuation of the new therapy
strategies, will allow the clinical management of these side effects
and result in continuing therapies with effective medications.
Bevacizumab, which is an IgG1 antibody against vascular endothelial
growth factor, has side effects such as proteinuria, hypertension,
venous and arterial thromboembolic events, and hemorrhage. This is the
first reported case of dural sinus vein thrombosis, during the
treatment with bevacizumab
Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab
The adverse effects of regimes in cancer treatment have forced us to
change to new targeted therapy options. Understanding these side
effects, which can lead to discontinuation of the new therapy
strategies, will allow the clinical management of these side effects
and result in continuing therapies with effective medications.
Bevacizumab, which is an IgG1 antibody against vascular endothelial
growth factor, has side effects such as proteinuria, hypertension,
venous and arterial thromboembolic events, and hemorrhage. This is the
first reported case of dural sinus vein thrombosis, during the
treatment with bevacizumab
Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma
Background: Prognostic factors related to survival in patients with inoperable metastatic or recurrent endometrial carcinoma (MREC) have remained unclear due to lack of clinical trials.The management of these patients is also controversial.This study was performed to compare the efficacy and toxicity profiles of two different systemic therapies (chemotherapy vs hormonal therapy) given for the treatment of patients with MREC and to identify the impact of various prognostic factors on the survival
Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer
Aims and background. It has been appreciated for some time that the lack of detection of ovarian cancer at clinical and pathological (second-look laparotomy) evaluation is not synonymous with cure. The goal of this study was to define clinical risk factors for recurrence after complete pathological response to postoperative chemotherapy in patients with epithelial ovarian cancer
The comparison of weekly and 3-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic SCCHN
THE PROGNOSTIC SIGNIFICANCE OF P21 AND HER-2 GENE EXPRESSION AND MUTATION/POLYMORPHISM IN PATIENTS WITH GASTRIC CARCINOMA
The Better Performance Status, the Better Outcome: Laryngeal Carcinoma Treated with Definitive Radiotherapy
Purpose: To evaluate the prognostic factors affecting locoregional control (LRC) and overall survival (OS) of patients with laryngeal carcinoma who were not candidates for surgical treatment due to tumour or host factors but were treated with definitive radiotherapy (RT)